Article Page

Abstract

We revisit the quantum features of an anti-ferromagnetic (AF) spin environment at finite temperature with gap in its frequency spectrum, on the dynamics quantum correlations of a coupled central two qubits system with Dzyaloshinskii-Moriya (DM) interaction, prepared in two entangled Bell states. Using entanglement and quantum discord as quantum meters of decoherence, the prepared entangled states are classified as robust or fragile relative to the degree of information leakage to the AF environment. By tailoring the size of the frequency gap, anisotropy field strength and induced field, due to system AF spin environment coupling, size of the AF environment and DM interaction parameter, a decoherence-free sub-space can be accessed for efficient execution of quantum protocols encoded in the entangled states Tailoring Quantum Correlations of a Coupled Central Two Qubits Soaked in a Finite Temperature Antiferromagnetic Environment with Frequency Gap the discovery of a potent aromatase/collagen IV derived biomimetic dual targeted small poly-active compound with future anti-tumor inhibitory activities.

Keywords

Tailoring Quantum Correlations; Coupled Central; Two Qubits; Soaked; Finite Temperature; Antiferromagnetic Environment; Frequency Gap; discovery; potent; aromatase/collagen IV; biomimetic; dual targeted; small poly-active compound;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Tailoring Quantum Correlations of a Coupled Central Two Qubits Soaked in a Finite Temperature Antiferromagnetic Environment with Frequency Gap the discovery of a potent aromatase/collagen IV derived biomimetic dual targeted small poly-active compound with future anti-tumor inhibitory activities.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available